drugset
drugset / Trial / NCT06966479

A Long-Term Safety and Efficacy Study of Verekitug (UPB-101) in Adult Participants With Severe Asthma (VALOUR)

NCT06966479 ↗

Phase 2 Active not recruiting 396 enrolled Upstream Bio Inc.
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The primary purpose of this study is to evaluate the long-term safety and efficacy of verekitug (UPB-101) in participants who complete the VALIANT study (NCT06196879).

Timeline

Start
2025-05-21
Primary completion
2027-09
Completion
2027-09

Drugs

EvaluationDrugModalityDoseRoute
Subject Verekitug Monoclonal antibody 100 mg Subcutaneous
Subject Verekitug Monoclonal antibody 400 mg Subcutaneous

Indications

asthma